Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma

Journal of Medicinal Chemistry

Volumn 50, Issue 15, 2007, Pages 3561-3572

  Pham, Tien Q ^a   Greguric, Ivan ^a   Liu, Xiang ^a   Berghofer, Paula ^a   Ballantyne, Patrice ^a   Chapman, Janette ^a   Mattner, Filomena ^a   Dikic, Branko ^a   Jackson, Timothy ^a   Loc'h, Christian ^a   Katsifis, Andrew ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO N [4 (N BUTYL N METHYLAMINO)BUTYL] 5 IODO 2 METHOXYBENZAMIDE; BENZAMIDE DERIVATIVE; HALOPERIDOL; IODINE 123; MELANIN; N [1 (2 FLUOROETHYL)PIPERIDIN 4 YL] 4 IODOBENZAMIDE; SIGMA 1 OPIATE RECEPTOR; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER MODEL; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; EVALUATION; FEMALE; ISOTOPE LABELING; MELANOMA; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ANALYSIS;

ACETANILIDES; ANIMALS; BENZAMIDES; BINDING, COMPETITIVE; HALOPERIDOL; IODINE RADIOISOTOPES; ISOTOPE LABELING; LIGANDS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PIPERIDINES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RECEPTORS, SIGMA; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS;

EID: 34547558289     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0701627     Document Type: Article

References (31)

1. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl. Med. Biol. 1999, 26, 687-693.
2. Allen, B. J.; Rizvi, S.; Li, Y.; Tian, Z.; Ranson, M. In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate, and colorectal cancers. Crit. Rev. Oncol. Hematol. 2001, 39, 139-146.
3. Coderre, J. A.; Packer, S.; Fairchild, R. G.; Greenberg, D.; Laster, B.; Micca, P.; Fand, I. Iodothiouracil as a melanoma localizing agent. J. Nucl. Med. 1986, 27, 1157-1164.
4. 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int. J. Cancer 2002, 101, 480-487.
5. Boyd, C. M.; Lieberman, L. M.; Beierwaltes, W. H.; Varma, V. M. Diagnostic efficacy of a radioiodinated chloroquine analog in patients with malignant melanoma. J. Nucl. Med. 1970, 11, 479-486.
6. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: Treatment of cutaneous tumors and lymph node metastases. Cancer Res. 1992, 52, 4385-4390.
7. Michelot, J. M.; Moreau, M. F.; Labarre, P. G.; Madelmont, J. C.; Veyre, A. J.; Papon, J. M.; Parry, D. F.; Bonafous, J. F.; Boire, J. Y.; Desplanches, G. G.; Bertrand, S. J.; Meyniel, G. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J. Nucl. Med. 1991, 32, 1573-1580.
8. Labarre, P.; Papon, J.; Moreau, M. F.; Moins, N.; Veyre, A.; Madelmont, J. C. Evaluation in mice of some iodinated melanoma imaging agents using cryosectioning and multi-wire proportional counting. Eur. J. Nucl. Med. 1999, 26, 494-498.
9. 123,131I]iodobenzamides by animal and cell-culture studies J. Labelled Cmpd. Radiopharm. 1995, 37, 260-262.
10. Dittmann, H.; Coenen, H. H.; Zolzer, F.; Dutschka, K.; Brandau, W.; Streffer, C. In vitro studies on the cellular uptake of melanoma imaging aminoalkyl-iodobenzamide derivatives (ABA). Nucl. Med. Biol. 1999, 26, 51-56.
11. John, C. S.; Bowen, W. D.; Saga, T.; Kinuya, S.; Vilner, B. J.; Baumgold, J.; Paik, C. H.; Reba, R. C.; Neumann, R. D.; Varma, V. M.; McAfee, J. G. A malignant melanoma imaging agent: Synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)-4-iodobenzamide. J. Nucl. Med. 1993, 34, 2169-2175.
12. Michelot, J. M.; Moreau, M. F.; Veyre, A. J.; Bonafous, J. F.; Bacin, F. J.; Madelmont, J. C.; Bussiere, F.; Souteyrand, P. A.; Mauclaire, L. P.; Chossat, F. M.; Papon, J. M.; Labarre, P. G.; Kauffmann, Ph.; Plagne, R. J. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J. Nucl. Med. 1993, 34, 1260-1266.
13. Brandau, W.; Niehoff, T.; Pulawski, P.; Jonas, M.; Dutschka, K.; Sciuk, J.; Coenen, H. H.; Schober, O. Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. J. Nucl. Med. 1996, 37, 1865-1871.
14. 123I-N-(2- diethylaminoethyl)-2-iodobenzamide: A potential imaging agent for cutaneous melanoma staging. Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 1478-1484.
15. Moins, N.; Papon, J.; Seguin, H.; Gardette, D.; Moreau, M. F.; Labarre, P.; Bayle, M.; Michelot, J.; Gramain, J. C.; Madelmont, J. C.; Veyre, A. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl. Med. Biol. 2001, 28, 799-808.
16. Eisenhut, M.; Hull, W. E.; Mohammed, A.; Mier, W.; Lay, D.; Just, W.; Gorgas, K.; Lehmann, W. D.; Haberkorn, U. Radioiodinated N-(2- diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J. Med. Chem. 2000, 43, 3913-3922.
17. Seguin, H.; Gardette, D.; Moreau, M. F.; Madelmont, J. C.; Gramain, J. C. A general method for the synthesis of N,N-dialkylaminobutylamines. Synth. Commun. 1998, 28, 4257-4272.
18. Marakarmi, M.; Inukai, N.; Koda, A.; Nakano, K. An improved synthesis of metoclopramide. Chem. Pharm. Bull. 1971, 19, 1696-1699.
19. Chehade, F.; De Labriolle-Vaylet, C.; Michelot, J.; Moins, N.; Moreau, M. F.; Hindie, E.; Papon, J.; Escaig, F.; Galle, P.; Veyre, A. Distribution of I-BZA (N-2-diethylaminoethyl-4-iodobenzamide) in grafted melanoma and normal skin: A study by secondary ion mass spectroscopy. Cell. Mol. Biol. 2001, 47, 529-534.
20. Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; Williams, W.; Bowen, W. D. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors; characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 1994, 268, 9-18.
21. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Tsung-Ping, S.; Tam, S. W.; Taylor, D. P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13, 85-86.
22. 2), an imaging agent for melanoma staging: Relation to pigmentation. Nucl. Med. Biol. 2005, 32, 451-458.
23. Chehade, F.; de Labriolle-Vaylet, C.; Moins, N.; Moreau, M. F.; Papon, J.; Labarre, P.; Galle, P.; Veyre, A.; Hindie, E. Secondary ion mass spectrometry as a tool for investigating radiopharmaceutical distribution at the cellular level: The example of I-BZA and (14)C-I-BZA. J. Nucl. Med. 2005, 46, 1701-1706.
24. John, C. S.; Vilner, B. J.; Geyer, B. C.; Moody, T.; Bowen, W. D. Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res. 1999, 59, 4578-4583.
25. 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: Initial studies in mouse tumor models. Nucl. Med. Biol. 1997, 24, 587-593.
26. Moreau, M. F.; Michelot, J.; Papon, J.; Bayle, M.; Labarre, P.; Madelmont, J. C.; Parry, D.; Boire, J. Y.; Moins, N.; Seguin, H.; Veyre, A.; Mauclaire, L. Synthesis, radiolabeling, and preliminary evaluation in mice of some (N-diethylaminoethyl)-4-iodobenzamide derivatives as melanoma imaging agents. Nucl. Med. Biol. 1995, 22, 737-747.
27. Alonso Garrido, D. O.; Buldain G.; Frydman B. Concerning the synthesis of N-methylputrescine and its homologs. J. Org. Chem. 1984, 49, 2021-2023.
28. Micovic, V. M.; Mihailovic, M. L. The reduction of acid amides with lithium aluminium hydride. J. Org. Chem. 1953, 18, 1190-1200.
29. Cassebaum, H.; Uhlig, K. Die Reaktion von N-(β- Halogenäthyl)-carbonsäureamiden mit Diäthylamin. J. Prakt. Chem. (Weinheim, Ger.) 1973, 315, 1057-1066.
30. Waterhouse, R. N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imaging Biol. 2003, 5, 376-389.
31. Chaki, S.; Tanaka, M.; Muramatsu, M.; Otomo, S. NE-100, a novel potent sigma ligand, preferentially binds to sigma 1 binding sites in guinea pig brain. Eur. J. Pharmacol. 1994, 251, R1-2.